To summarize advancements in chemotherapy for breast cancer, focusing on predictive markers, resistance mechanisms, and therapeutic strategies.
Approach:
Clinical Trials: Dewidar et al. reported on an open-label clinical trial (NCT06186700) evaluating pentoxifylline in 106 breast cancer patients undergoing AC/T chemotherapy, finding it significantly reduced the incidence of grade 2 or higher peripheral sensory neuropathy and mucositis. Iqbal et al. conducted a randomized, placebo-controlled trial (NCT06459193) that found trimetazidine significantly decreased the incidence of grade 2–3 paclitaxel-induced peripheral neuropathy.
Hypothesis and Theory: Li et al. proposed the Selective Lipid Metabolism Therapy Benefit Hypothesis, emphasizing the need for predictive biomarkers in targeting lipid metabolism in breast cancer.
Original Articles: Various studies explored prognostic tools and treatment responses, including an 18-gene AICD signature, the Systemic Immune-Inflammation Index, and predictors for triple-negative breast cancer outcomes.
Key Findings:
Pentoxifylline significantly reduced the incidence of chemotherapy-induced peripheral sensory neuropathy and mucositis.
Trimetazidine was effective in reducing paclitaxel-induced neuropathy and improving quality of life.
The Systemic Immune-Inflammation Index may serve as a prognostic tool for breast cancer incidence and mortality.
High biopsy-sTILs and other factors predicted pathological complete response in triple-negative breast cancer.
Therapeutic drug monitoring of docetaxel can optimize dosing and minimize toxicity.
Interpretation:
The editorial highlights significant advancements in understanding and managing breast cancer chemotherapy, particularly through predictive biomarkers and treatment strategies.
Limitations:
The studies reviewed may have varying sample sizes and methodologies, which could affect the generalizability of findings.
Further large-scale studies are needed to validate the effectiveness of proposed treatments and biomarkers.
Conclusion:
The editorial summarizes key research advancements in breast cancer chemotherapy, focusing on predictive biomarkers and treatment strategies.
